RATINGS CHANGES

AmerisourceBergen (ABC - Get Report) was upgraded to overweight from equal-weight at Morgan Stanley. $89 price target. The industry should benefit from the election, Morgan said. 

Franklin Resources (BEN - Get Report) was downgraded to sell from hold at Deutsche Bank. The valuation is less attractive, based on a $35 price target, Deutsche said. 

Chesapeake (CHK - Get Report) was upgraded to hold from underperform at Jefferies. $5 price target. The company is on firmer financial footing, Jefferies said. 

CSX (CSX - Get Report) was downgraded to market perform at BMO Capital. $35 price target. There is excess capacity in the truck market and cost savings are likely to decelerate, BMO said. 

Humana (HUM - Get Report) was upgraded to overweight from neutral at JPMorgan. $202 price target. Underlying earnings power is improving, JPMorgan said. 

IBM (IBM - Get Report) was upgraded to buy from neutral at Bank of America/Merrill Lynch. $185 price target. The company has multiple potential earnings levers, analysts said. 

Northrop Grumman (NOC) was upgraded to overweight from equal-weight at Barclays. $270 price target. The company is leveraged to higher overall spending, Barclays said. 

Oasis (OAS - Get Report) was upgraded to buy from hold at Deutsche Bank. $16 price target. The company can benefit from lower crude oil prices, Deutsche said. 

Universal Display (OLED - Get Report) was downgraded to hold at TheStreet Ratings. You can view the full analysis from the report here: OLED.

OneMain (OMG) was downgraded to equal-weight at Barclays. $19 price target. The valuation is less attractive, as the company slashed earnings guidance, Barclays said. 

Qualcomm (QCOM - Get Report) was downgraded to equal-weight from overweight at Morgan Stanley. The valuation is less attractive, based on a $65 price target, Morgan said. 

ViaSat (VSAT - Get Report) was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: VSAT.

WellCare Health Plans (WCG - Get Report) was downgraded to neutral from overweight at JPMorgan. $115 price target. The valuation is less attractive, as the company is facing new political risks, JPMorgan said. 

This article was written by a staff member of TheStreet.